^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ifabotuzumab (KB004)

    i
    Other names: KB004 , KB-004
    Company:
    Humanigen, Olivia Newton-John Cancer Research Institute, Taran Therapeutics
    Drug class:
    EphA3 inhibitor
    23h
    A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma. (PubMed, Clin Cancer Res)
    Targeting EphA3 with ifabotuzumab in glioblastoma patients is safe and attractive, showing chronological stable expression across both tumour compartments (particularly in cells with mesenchymal phenotype) and non-tumour compartments (particularly the vascular compartment) with evidence of target modulation.
    P1 data • Journal
    |
    EPHA3 (EPH receptor A3)
    |
    ifabotuzumab (KB004)
    over4years
    A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
    P1, N=12, Completed, Olivia Newton-John Cancer Research Institute | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EPHA3 (EPH receptor A3)
    |
    ifabotuzumab (KB004)
    almost5years
    A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Trial completion date: Apr 2021 --> Sep 2021
    Clinical • Trial completion date
    |
    EPHA3 (EPH receptor A3)
    |
    ifabotuzumab (KB004)